Summary
Nocturia pipeline research report is a part of our 300+ Pharmaceutical and Healthcare disease pipeline report series. It provides detailed insights into Nocturia R&D activities including pipeline candidates, grants, developments, investments, technological advancements, and progress.
Extensive Coverage of Pipeline Candidates
The Nocturia report covers all the pre-clinical compounds and clinical compounds under evaluation for treatment of Nocturia as of 2019. All preclinical, research, discovery, pre registration, phase 1, phase 2, and phase 3 trials active are included in the study.
Over 10 descriptive details provided for each Pipeline Product
Complete analysis of therapeutics for treatment of Nocturia with details of current status of development, pipeline phase, drug target, mechanism of action (MoA), route of administration (RoA), participating companies, originator, collaborators and molecule type are included. The study also covers the historic developments, pharmacological action and recent developments associated with each drug.
Companies participating in Nocturia pipeline Profiled in detail
Key players actively participating in Nocturia pipeline are profiled along with their R&D progress in Nocturia treatment are provided. Companies /Universities /Institutes participating as originators, collaborators, licensors, investors, and marketing or developing companies are detailed in the report. Further, for all the developing companies, detailed profile is also provided.
Information Sourced from in-house Proprietary Databases
The report is developed using information from in-house database developed over years through daily updates from company reports, websites, events, conferences, news, announcements, clinical trial registries, regulatory authorities, universities and industry associations.
Report assists users in taking actionable steps
Nocturia pipeline report enables users to gain clear understanding into large and small companies participating in the pipeline and detailed insights into their product portfolio. The guide presents also available opportunities for new business in Nocturia treatment pipeline.
The report includes:
Nocturia pipeline research report is a part of our 300+ Pharmaceutical and Healthcare disease pipeline report series. It provides detailed insights into Nocturia R&D activities including pipeline candidates, grants, developments, investments, technological advancements, and progress.
Extensive Coverage of Pipeline Candidates
The Nocturia report covers all the pre-clinical compounds and clinical compounds under evaluation for treatment of Nocturia as of 2019. All preclinical, research, discovery, pre registration, phase 1, phase 2, and phase 3 trials active are included in the study.
Over 10 descriptive details provided for each Pipeline Product
Complete analysis of therapeutics for treatment of Nocturia with details of current status of development, pipeline phase, drug target, mechanism of action (MoA), route of administration (RoA), participating companies, originator, collaborators and molecule type are included. The study also covers the historic developments, pharmacological action and recent developments associated with each drug.
Companies participating in Nocturia pipeline Profiled in detail
Key players actively participating in Nocturia pipeline are profiled along with their R&D progress in Nocturia treatment are provided. Companies /Universities /Institutes participating as originators, collaborators, licensors, investors, and marketing or developing companies are detailed in the report. Further, for all the developing companies, detailed profile is also provided.
Information Sourced from in-house Proprietary Databases
The report is developed using information from in-house database developed over years through daily updates from company reports, websites, events, conferences, news, announcements, clinical trial registries, regulatory authorities, universities and industry associations.
Report assists users in taking actionable steps
Nocturia pipeline report enables users to gain clear understanding into large and small companies participating in the pipeline and detailed insights into their product portfolio. The guide presents also available opportunities for new business in Nocturia treatment pipeline.
The report includes:
- The research work provides comprehensive overview of Nocturia pipeline and treatment landscape
- Complete list of drug candidates from discovery to pre-registration phases are analyzed
- Companies and universities participating in the pipeline are analyzed in detail along with their drug development product portfolio
- Detailed drug profiles of Nocturia pipeline compounds including status, phase, mechanism of action, route of administration, originators, licensing and collaborating companies, grants, technological advancements and investments are detailed
- Research and Development progress and trial details, results wherever available, are also included in the Nocturia pipeline study
- All recent news and developments related to Nocturia drugs are provided
Table of Contents
1. Introduction
3. Nocturia R&D Pipeline Trends
4. Nocturia Pre-clinical and Discovery Phase Drug Profiles
5. Nocturia Clinical Phase Drug Profiles
6. Company Profiles
8. Appendix
Companies Mentioned
- Ferring International Center S
- Sanwa Kagaku Kenkyusho Co Ltd
- Serenity Pharmaceuticals LLC
- Tacurion Pharma Inc
- Vantia Ltd
- Wellesley Pharmaceuticals LLC
